Procore signs multi-year strategic collaboration agreement with AWS
HOUSTON - Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotech company with a market capitalization of approximately $110 million, announced progress on its platform for regulatory T cell-derived exosome (Treg exosomes) treatments aimed at chronic inflammation linked to neurodegenerative diseases. According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet. The company’s research has shown that Treg exosomes can suppress inflammation effectively in preclinical models, offering a potential new approach to treating conditions like autoimmune and neurodegenerative diseases.
Fred Grossman, DO, Coya’s Chief Medical Officer, emphasized the company’s commitment to developing an "off the shelf" modality that could serve as a first-in-class disease-modifying treatment for neurodegenerative diseases with high unmet need. The company’s Treg exosomes have displayed several advantages, including resistance to conversion to non-suppressive phenotypes in inflammatory environments, as they are not cells.
Coya has completed initial engineering batches of Treg exosomes using expanded Tregs from healthy donors in the first quarter of 2025. The Johnson Center for Cellular Therapeutics is now focusing on additional manufacturing runs to ensure the reproducibility and quality of the exosomes. The company plans to begin Good Manufacturing Practice (GMP) manufacturing of larger-scale clinical batches before the end of 2025, in preparation for a first-in-human study.
The development of Treg exosomes is supported by partnerships, including the Johnson Center, and funding from organizations such as Hop On A Cure and Energy Transfer. Coya holds exclusive rights for the clinical application of the Treg exosome technology.
This press release includes forward-looking statements regarding Coya’s product development and clinical plans, reflecting management’s current beliefs and based on information available at this time. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Investors should note that Coya’s next earnings report is scheduled for May 8, 2025. For deeper insights into Coya’s financial health and additional ProTips, consider subscribing to InvestingPro, which offers comprehensive analysis and valuation metrics for informed investment decisions.
The information in this article is based on a press release statement from Coya Therapeutics, Inc.
In other recent news, Coya Therapeutics has reported promising results from a Phase 2 study evaluating their low-dose interleukin-2 (LD IL-2) therapy in Alzheimer’s disease patients. The study, conducted over five months, showed statistically significant reductions in pro-inflammatory markers and improvements in cognitive function, as evidenced by a 4.93-point improvement in the ADAS-Cog score compared to placebo. Coya’s Chief Medical Officer highlighted the potential benefits of targeting regulatory T cells in neurodegenerative disorders. Additionally, BTIG analysts have maintained their Buy rating and $15 price target for Coya Therapeutics, citing clinical trial data that supports the effectiveness of monthly dosing of their COYA301 treatment. The analysts emphasized the anti-inflammatory effects observed and the potential of COYA303, a combination therapy involving low-dose IL-2 and a GLP-1 receptor agonist, in treating Alzheimer’s disease. Furthermore, Coya Therapeutics is advancing COYA 303 for inflammatory diseases, with plans to publish preclinical study results in 2025. The company is also preparing to progress COYA 303 through clinical trials, highlighting the potential synergistic effects of its dual immunomodulatory action.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.